» Articles » PMID: 29937995

Identifying Patients with an Unfavorable Prognosis in Early Stages of Colorectal Carcinoma

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Jun 26
PMID 29937995
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In recent years, the concept of liquid biopsy diagnostics in detection and progress monitoring of malignant diseases gained significant awareness. We here report on a semi-quantitative real-time cytokeratin 20 RT-PCR-based assay, for detecting circulating tumor cells within a fraction of peripheral blood mononuclear cells in colorectal cancer patients.

Methods: In total, 381 patients were included. Prior to surgical tumor resection, a peripheral blood sample was drawn. Mononuclear cells were isolated by Ficoll centrifugation and a cytokeratin 20 qRT-PCR assay was performed. Quantitative PCR data was assessed regarding histopathological characteristics and patients´ clinical outcome.

Results: A cut-off value was determined at ≥ 2.77 [EU]. Stratifying patients by this cut-off, it represents a statistically highly significant prognostic marker for both the overall and disease-free survival in the entire cohort UICC I-IV (both p<0.001) and in early tumor stages UICC I+II (overall survival p=0.003 and disease-free survival p=0.005). In multivariate analysis, the cut-off value stands for an independent predictor of significantly worse overall and disease-free survival (p=0.035 and p=0.047, respectively).

Conclusion: We successfully established a highly sensitive real-time qRT-PCR assay by which we are able to identify colorectal cancer patients at risk for an unfavorable prognosis in UICC I and II stages.

Citing Articles

Detection of Circulating and Disseminated Tumor Cells and Their Prognostic Value under the Influence of Neoadjuvant Therapy in Esophageal Cancer Patients.

Richter F, Roder C, Moller T, Egberts J, Becker T, Sebens S Cancers (Basel). 2022; 14(5).

PMID: 35267585 PMC: 8909540. DOI: 10.3390/cancers14051279.


Detection of Marker Associated with CTC in Colorectal Cancer in Mononuclear Cells of Patients with Benign Inflammatory Intestinal Diseases.

Born J, Hendricks A, Hauser C, Egberts J, Becker T, Roder C Cancers (Basel). 2022; 14(1).

PMID: 35008210 PMC: 8750406. DOI: 10.3390/cancers14010047.


Longitudinal Analysis of Circulating Tumor Cells in Colorectal Cancer Patients by a Cytological and Molecular Approach: Feasibility and Clinical Application.

Hendricks A, Dall K, Brandt B, Geisen R, Roder C, Schafmayer C Front Oncol. 2021; 11:646885.

PMID: 34262858 PMC: 8273730. DOI: 10.3389/fonc.2021.646885.


Isolation and Enumeration of CTC in Colorectal Cancer Patients: Introduction of a Novel Cell Imaging Approach and Comparison to Cellular and Molecular Detection Techniques.

Hendricks A, Brandt B, Geisen R, Dall K, Roder C, Schafmayer C Cancers (Basel). 2020; 12(9).

PMID: 32947903 PMC: 7563529. DOI: 10.3390/cancers12092643.


MicroRNA-128 targeting RPN2 inhibits cell proliferation and migration through the Akt-p53-cyclin pathway in colorectal cancer cells.

Zhou T, Wu L, Wang Q, Jiang Z, Li Y, Ma N Oncol Lett. 2018; 16(6):6940-6949.

PMID: 30546426 PMC: 6256417. DOI: 10.3892/ol.2018.9506.

References
1.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012; 30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836. View

2.
Chaffer C, Weinberg R . A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. DOI: 10.1126/science.1203543. View

3.
Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C . Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2014; 26(1):13-21. DOI: 10.1093/annonc/mdu378. View

4.
Flatmark K, Borgen E, Nesland J, Rasmussen H, Johannessen H, Bukholm I . Disseminated tumour cells as a prognostic biomarker in colorectal cancer. Br J Cancer. 2011; 104(9):1434-9. PMC: 3101945. DOI: 10.1038/bjc.2011.97. View

5.
Gorges T, Tinhofer I, Drosch M, Rose L, Zollner T, Krahn T . Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012; 12:178. PMC: 3502112. DOI: 10.1186/1471-2407-12-178. View